Chemical and Biomolecular Engineering, Department of
Department of Chemical and Biomolecular Engineering: Faculty Publications
Accessibility Remediation
If you are unable to use this item in its current form due to accessibility barriers, you may request remediation through our remediation request form.
Date of this Version
2008
Document Type
Article
Citation
Glycobiology vol. 18 no. 7 pp. 526–539, 2008
Abstract
Glycosylation of recombinant proteins is of particular
importance because it can play significant roles in the
clinical properties of the glycoprotein. In this work, the
N-glycan structures of recombinant human Factor IX (tg-
FIX) produced in the transgenic pig mammary gland were
determined. Themajority of theN-glycans of transgenic pigderived
Factor IX (tg-FIX) are complex, bi-antennary with
one or two terminal N-acetylneuraminic acid (Neu5Ac) moieties.
We also found that the N-glycan structures of tg-FIX
produced in the porcine mammary epithelial cells differed
with respect to N-glycans from glycoproteins produced in
other porcine tissues. tg-FIX contains no detectableNeu5Gc,
the sialic acid commonly found in porcine glycoproteins produced
in other tissues.Additionally,wewere unable to detect
glycans in tg-FIX that have a terminal Galα(1,3)Gal disaccharide
sequence, which is strongly antigenic in humans.
The N-glycan structures of tg-FIX are also compared to the
publishedN-glycan structures of recombinant human glycoproteins
produced in other transgenic animal species.While
tg-FIX contains only complex structures, antithrombin III
(goat), C1 inhibitor (rabbit), and lactoferrin (cow) have both
high mannose and complex structures. Collectively, these
data represent a beginning point for the future investigation
of species-specific and tissue/cell-specific differences in
N-glycan structures among animals used for transgenic animal
bioreactors.
Comments
Copyright The Author 2008. Published by Oxford University Press. All rights reserved.